Sonelokimab for psoriatic arthritis after TNF inhibitor failure
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study tests an investigational drug called sonelokimab for people with active psoriatic arthritis who have already tried a TNF-alpha inhibitor (like adalimumab) and it didn't work well enough. The goal is to see if sonelokimab can reduce joint pain and swelling and improve skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have psoriatic arthritis diagnosed for at least 6 months
- You currently have at least 3 tender joints and 3 swollen joints
- You have active psoriasis now or had it in the past (confirmed by a dermatologist)
- You have tried one or more TNF-alpha inhibitors (like adalimumab, etanercept, or infliximab) and they didn't work well enough or you had to stop due to side effects
- You do not have other chronic inflammatory conditions (like rheumatoid arthritis, lupus, or inflammatory bowel disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have already been in a previous trial of sonelokimab for psoriatic arthritis and want to continue treatment. It checks how safe and effective the medicine is over a longer time.
This trial tests a new medication called icotrokinra for people with active psoriatic arthritis (PsA). It aims to see how well the drug works and if it is safe, including for those who have tried other treatments.
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
This study tests an experimental drug called JNJ-88545223 to see if it can reduce joint pain, swelling, and skin plaques in people with active psoriatic arthritis. It may help if you have both joint symptoms and psoriasis.
This study tests an oral medicine called zasocitinib for people with psoriatic arthritis who have not had enough relief from other treatments. It may help reduce joint pain and skin symptoms.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
Hear when a new Arthritis, Psoriatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.